This trial is active, not recruiting.

Conditions vegfc protein in serum, vegfc protein in non small cell lung cancer, vegfc protein in escc, cttn protein in escc, mir326 in escc and non small cell lung cancer
Sponsor China Medical University Hospital
Start date October 2010
Trial size 250 participants
Trial identifier NCT01240369, DMR99-IRB-206


Lung cancer and esophageal cancer remain the leading causes of cancer death worldwide. The main problem is lack of effective tool in early detection that accounts for the poor outcome of cancer. Clinically, over 80% of patients with cancer were at late stage when they were diagnosed. Therefore, it is important for us to find the biomarker that serve as the early prediction of cancer.

The investigators have published that VEGFC over-expressed in non-small cell lung cancer. VEGFC plays a critical role in regulating motility of tumor cells, promotes proliferation of lymphatic endothelial cells and enhances migration and invasion. Investigator found that VEGFC over-expressed in the serum of esophageal cancer patients. Therefore, it is worthwhile to investigate the correlation between VEGFC, clinical lung cancer and esophageal cancer.

MicroRNAs (miRNAs) are conserved, endogenous, small, and noncoding RNA molecules of 21~23 nucleotides that function as post-transcriptional gene regulators. Recent studies indicated that certain microRNAs reduced in cancer patients. Therefore it is important to investigate whether specific microRNA changed in certain kinds of cancer patients.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective cross-sectional

Eligibility Criteria

Male or female participants from 50 years up to 80 years old.

Inclusion Criteria: - tumor size > 0.5 cm3 Exclusion Criteria: - tumor size < 0.5 cm3

Trial information was received from ClinicalTrials.gov and was last updated in November 2010.
Information provided to ClinicalTrials.gov by China Medical University Hospital.